SARS-CoV-2 Panels & Controls for Coronavirus Testing Quality Control, Research, and Assay Development
Coronaviruses (CoV) are common throughout the world and are part of a large family of viruses that cause illnesses ranging from the common cold to the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). Today we are faced with SARS-CoV-2 which is rapidly spreading itself globally.
The potential global health risk posed by SARS-CoV-2 is extremely high as the influenza-like illness ranges from mild symptoms to severe illness and possible death. Current confirmed cases are seeing prolific growth daily and CDC recommendations for infection prevention and control is evolving quickly.
As we strive to better understand SARS-CoV-2 and look forward to providing developers and laboratories with safe to use, non-infectious external quality controls, we recommend a review of our current Coronavirus products which may provide some utility in your assay development and/or research and analytical studies.
- NATtrol molecular Controls are non-infectious, ready-to-use, whole organisms which are designed to evaluate performance of molecular tests. They can be used for verification of assays, training of laboratory personnel and to monitor assay-kit lot performance.
- Heat-inactivated viral culture fluids are designed for molecular based testing.
- Purified heat-inactivated lysates are intended for research, product development, manufacturing, and quality assurance testing. Viral lysates can be used as an antigen, as a source for the purification of viral proteins, or in assays for the detection of viral antibodies.
Organism / Strain | Part Number | Product Description | Classification |
SARS-CoV-2 |
|||
Multiple Target/Variant Panels | |||
Coronavirus 229E, Coronavirus HKU-1, Coronavirus NL63, Coronavirus OC43, SARS-CoV-2: USA-WA1/20204, Adenovirus 3, B. pertussis, C. pneumoniae, Influenza A 2009 H1N1pdm, Influenza A H1N1, Influenza A H3N2, Influenza B, M. pneumoniae, Metapneumovirus 8, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Rhinovirus 1A, RSV A, Negative | NATRVP2-QIA |
NATtrol Respiratory Verification Panel 2 (21 x 0.25 mL)
|
RUO |
SARS-CoV-2: USA-WA1/2020, Coronavirus 229E, Coronavirus HKU-1, Coronavirus NL63, Coronavirus OC43, Adenovirus 1, Adenovirus 3, Adenovirus 31, B. parapertussis, B. pertussis, C. pneumoniae, Influenza A 2009 H1N1pdm, Influenza AH1, M. pneumoniae, Parainfluenza 1, Parainfluenza 4, Rhinovirus 1A, Influenza B, Parainfluenza 2, Parainfluenza 3, RSV A, Influenza A H3N2, Metapneumovirus 8, Negative | NATRVP2.1-BIO |
NATtrol Respiratory Verification Panel 2.1 (24 x 0.6 mL)
|
RUO |
SARS-CoV-2: USA-WA1/2020, Coronavirus 229E, Coronavirus HKU-1, Coronavirus NL63, Coronavirus OC43, Adenovirus 1, Adenovirus 3, Adenovirus 31, B. parapertussis, B. pertussis, C. pneumoniae, Influenza A 2009 H1N1pdm, Influenza AH1, M. pneumoniae, Parainfluenza 1, Parainfluenza 4, Rhinovirus 1A, Influenza B, Parainfluenza 2, Parainfluenza 3, RSV A, Influenza A H3N2, Metapneumovirus 8, Negative | NATRPC2.1-BIO |
NATtrol Respiratory Panel 2.1 Controls (12 x 0.3 mL)
|
RUO |
Alpha (B.1.1.7) England/204820464/2020; Beta (B.1.351) South Africa/ KRISP-K005325/2020; Delta (B.1.617.2) USA/PHC658/2021; Gamma (P.1) Japan/TY7-503/2021 |
NATSARS(COV2)-VP |
NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL)
|
RUO |
Omicron B.1.1.529 | |||
B.1.1.529 BA.1: Isolate: USA/MD-HP20874/2021 | NATCOV2(OMC)-ERC | NATtrol SARS-CoV-2 Omicron External Run Control (6 x 0.5 mL) Target concentration: 50,000 copies/mL |
RUO |
B.1.1.529 BA.1: Isolate: USA/MD-HP20874/2021 | 0810642CFHI | SARS-CoV-2 Omicron Heat-Inactivated CF (1 mL) | RUO |
B.1.1.529 BA.2: Isolate: USA/MD-HP24556/2022 | 0810643CFHI | SARS-CoV-2 Omicron Heat-Inactivated CF (1 mL) | RUO |
USA-WA1/2020 | |||
SARS-COV-2: USA-WA1/2020, Influenza A: A/Brisbane/10/07, Influenza B: B/Florida/02/06, RSVB: CH93(18)-18 |
NATFRC-6C |
NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5 mL) |
RUO |
SARS-COV-2: USA-WA1/2020, Influenza A: A/Brisbane/10/07, Influenza B: B/Florida/02/06, RSVB: CH93(18)-18 |
NATFRC-6C-IVD |
NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5 mL) To be used with NATCV9-6C-IVD |
CE IVD |
SARS-COV-2: USA-WA1/2020, Influenza A: A/Brisbane/10/07, Influenza B: B/Florida/02/06, RSVB: CH93(18)-18 |
NATFRC-ERC | NATtrol Flu/RSV/SARS-CoV-2 External Run Control (6 x 0.5 mL) Target concentration: 15,000 copies/mL |
RUO |
Isolate: USA-WA1/2020 | NATSARS(COV2)-ST | NATtrol SARS-CoV-2 Stock Target concentration: 1,000,000 copies/mL |
RUO |
Isolate: USA-WA1/2020 | NATSARS(COV2)-ERC | NATtrol SARS-CoV-2 External Run Control (6 x 0.5 mL) Target concentration: 50,000 copies/mL |
RUO |
Isolate: USA-WA1/2020 | NATSARS(COV2)-ERC-IVD | NATtrol SARS-CoV-2 External Run Control (6 x 0.5 mL) Target concentration: 50,000 copies/mL |
CE IVD |
Isolate: USA-WA1/2020 | NATSARS(COV2)-ERC1 | NATtrol SARS-CoV-2 External Run Control (6 x 1.0 mL) Target concentration: 50,000 copies/mL |
RUO |
Isolate: USA-WA1/2020 | NATSARS(COV2)-ERC1-IVD | NATtrol SARS-CoV-2 External Run Control (6 x 1.0 mL) Target concentration: 50,000 copies/mL |
CE IVD |
Isolate: USA-WA1/2020 | 0810587 | SARS-CoV-2 Lysate (1 mg) | RUO |
Isolate: USA-WA1/2020 | 0810587-0.5mg | SARS-CoV-2 Lysate (0.5 mg) | RUO |
Isolate: USA-WA1/2020 | 0810587CFHI-0.5mL | SARS-CoV-2 Heat-Inactivated CF (0.5 mL) | RUO |
Isolate: USA-WA1/2020 | 0810587CFHI | SARS-CoV-2 Heat-Inactivated CF (1 mL) | RUO |
Italy-INMI1 | |||
Isolate: Italy-INMI1 | 0810589CFHI | SARS-CoV-2 Heat-Inactivated CF (1 mL) | RUO |
Hong Kong/VM20001061/2020 | |||
Isolate: Hong Kong/VM20001061/2020 | 0810590CFHI | SARS-CoV-2 Heat-Inactivated CF (1 mL) | RUO |
USA/NY-Wadsworth-103677-01/2020 | |||
B.1_2020: Isolate: USA/NY-Wadsworth-103677-01/2020 | 0810621CFHI | SARS-CoV-2 Heat-Inactivated CF (1 mL) | RUO |
USA/NY-Wadsworth-33126-01/2020 | |||
B.1.595_2020: Isolate: USA/NY-Wadsworth-33126-01/2020 | 0810622CFHI | SARS-CoV-2 Heat-Inactivated CF (1 mL) | RUO |
Alpha B.1.1.7 | |||
B.1.1.7: Isolate: England/204820464/2020 | NATSARS(COV2-UK)-ST | NATtrol SARS-CoV-2 Alpha Stock (1 mL) Target concentration: 1,000,000 copies/mL |
RUO |
B.1.1.7: Isolate: England/204820464/2020 | 0810614CFHI | SARS-CoV-2 Alpha Heat-Inactivated CF (1 mL) | RUO |
B.1.1.7: Isolate: USA/CA_CDC_5574/2020 | 0810612CFHI | SARS-CoV-2 Alpha Heat-Inactivated CF (1 mL) | RUO |
Beta B.1.351 | |||
B.1.351: Isolate: South_Africa/KRISP-K005325/2020 | NATSARS(COV2-SA)-ST | NATtrol SARS-CoV-2 Beta Stock (1 mL) Target concentration: 1,000,000 copies/mL |
RUO |
B.1.351: Isolate: South_Africa/KRISP-K005325/2020 | 0810613CFHI | SARS-CoV-2 Beta Heat-Inactivated CF (1 mL) | RUO |
Gamma P1 | |||
P1: Isolate: Japan/TY7-503/2021 | 0810616CFHI | SARS-CoV-2 Gamma Heat-Inactivated CF (1 mL) | RUO |
P1_2021: Isolate: NY-Wadsworth-21033899-01/2021 | 0810617CFHI | SARS-CoV-2 Gamma Heat-Inactivated CF (1 mL) | RUO |
Zeta P2 | |||
P2_2021: Isolate: NY-Wadsworth-21006055-01/2021 | 0810618CFHI | SARS-CoV-2 Zeta Heat-Inactivated CF (1 mL) | RUO |
Iota B.1.526 | |||
B.1.526_2021: Isolate: USA/NY-Wadsworth-21025952-01/2021 Isolate 1 | 0810619CFHI | SARS-CoV-2 Iota Heat-Inactivated CF (1 mL) | RUO |
B.1.526_2021: Isolate: USA/NY-Wadsworth-21018781-01/2021 Isolate 2 | 0810620CFHI | SARS-CoV-2 Iota Heat-Inactivated CF (1 mL) | RUO |
Kappa B.1.617.1 | |||
B.1.617.1: Isolate: USA/CA-Stanford-15_S02/2021 | 0810623CFHI | SARS-CoV-2 Kappa Heat-Inactivated CF (1 mL) | RUO |
Delta B.1.617.2 | |||
B.1.617.2: Isolate: USA/PHC658/2021 | 0810624CFHI | SARS-CoV-2 Delta Heat-Inactivated CF (1 mL) | RUO |
Negative Controls | |||
Coxsackievirus A9 | NATCV9-6C |
NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5 mL) |
RUO |
Coxsackievirus A9 | NATCV9-6C-IVD |
NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5 mL) To be used with NATFRC-6C-IVD |
CE IVD |
VeroE6 cells | 0820010CFHI | SARS-CoV-2 Heat-Inactivated CF Negative control (1 mL) | RUO |
A-549 cells | NATSARS(COV2)-NEG | NATtrol Negative Control (6 x 0.5 mL) Target concentration: 50,000 cells/mL |
RUO |
A-549 cells | NATSARS(COV2)-NEG-IVD | NATtrol Negative Control (6 x 0.5 mL) Target concentration: 50,000 cells/mL |
CE IVD |
A-549 cells | NATSARS(COV2)-NEG1 | NATtrol Negative Control (6 x 1.0 mL) Target concentration: 50,000 cells/mL |
RUO |
A-549 cells | NATSARS(COV2)-NEG1-IVD | NATtrol Negative Control (6 x 1.0 mL) Target concentration: 50,000 cells/mL |
CE IVD |
SARS | |||
2003-00592 | NATSARS-ST | NATtrol Coronavirus Stock (1 mL) | RUO |
Seasonal Coronavirus | |||
229E | |||
229E | NATCOV(229E)-ST | NATtrol Coronavirus Stock (1 mL) Target ct range: 22–25 |
RUO |
229E | 0810229CF | Coronavirus CF (1 mL) | RUO |
229E | 0810229CFHI | Coronavirus Heat-Inactivated CF (1 mL) | RUO |
229E | 0810229 | Coronavirus Lysate (1 mg) | RUO |
NL63 | |||
NL63 | NATCOV(NL63)-ST | NATtrol Coronavirus Stock (1 mL) Target ct range: 22–25 |
RUO |
NL63 | 0810228CF | Coronavirus CF (1 mL) | RUO |
NL63 | 0810228CFHI | Coronavirus Heat-Inactivated CF (1 mL) | RUO |
NL63 | 0810228 | Coronavirus Lysate (1 mg) | RUO |
OC43 | |||
OC43 | 0810024CF | Coronavirus CF (1 mL) | RUO |
OC43 | 0810024CFHI | Coronavirus Heat-Inactivated CF (1 mL) | RUO |
OC43 | 0810024 | Coronavirus Lysate (1 mg) | RUO |
MERS-CoV | |||
Florida/USA-2_Saudi Arabia_2014 | NATMERS-ST | NATtrol MERS-CoV Stock (1 mL) Target ct range: 22–28 |
RUO |
Florida/USA-2_Saudi Arabia_2014 US sales only | 0810575CFHI | MERS-CoV Heat-Inactivated CF (1 mL) | RUO |